FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Daryl T-Y Lau

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Anatomy

Livers

Concepts & Ideas

Time Factors

Co-author Network

Publications

TOP 3
Amina A Negash; Neven Papic; Hilario J Ramos; Curt H Hagedorn; Juandy Jo; Daryl T-Y Lau; Antonio Bertoletti; Nanette Crochet; Don A Delker; Brian Doehle; Michael Gale
IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease.
Courtney Wilkins; Jessica Woodward; Amy Barnes; Michael Joyce; Daryl T-Y Lau; Nicola McFarlane; Jane A McKeating; D Lorne Tyrrell; Michael Gale
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry.
Elliot B Tapper; Daryl T-Y Lau
The need for clarity in occult HBV infection.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Daryl T-Y Lau (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Amina A Negash; Neven Papic; Hilario J Ramos; Curt H Hagedorn; Juandy Jo; Daryl T-Y Lau; Antonio Bertoletti; Nanette Crochet; Don A Delker; Brian Doehle; Michael Gale
IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease.
PLoS pathogens 2013;9(4):e1003330.
2013: Courtney Wilkins; Jessica Woodward; Amy Barnes; Michael Joyce; Daryl T-Y Lau; Nicola McFarlane; Jane A McKeating; D Lorne Tyrrell; Michael Gale
IFITM1 is a tight junction protein that inhibits hepatitis C virus entry.
Hepatology (Baltimore, Md.) 2013;57(2):461-9.
2011: Elliot B Tapper; Daryl T-Y Lau
The need for clarity in occult HBV infection.
Journal of viral hepatitis 2011;18(10):673-4.
2008: Daryl T-Y Lau; Wissam Bleibel
Current status of antiviral therapy for hepatitis B.
Therapeutic advances in gastroenterology 2008;1(1):61-75.
2008: Daryl T-Y Lau; Penny Mar Fish; Mala Sinha; David M Owen; Stanley M Lemon; Michael Gale
Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients.
Hepatology (Baltimore, Md.) 2008;47(3):799-809.
2007: Robert G Gish; Daryl T-Y Lau; Peter Schmid; Robert P Perrillo
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
The American journal of gastroenterology 2007;102(12):2718-23.
2007: Usman Khokhar; Linda K Shipton; Debra Stevens; Daryl T-Y Lau
Review.
Gastroenterology & hepatology 2007;3(9):727-30.
2007: Ned Snyder; Audrey Nguyen; Leka Gajula; Roger Soloway; Shu-Yuan Xiao; Daryl T-Y Lau; John Petersen
The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C.
Clinica chimica acta; international journal of clinical chemistry 2007;381(2):119-23.
2007: Rakesh L Tripathi; Preethi Krishnan; Yupeng He; Tim Middleton; Tami Pilot-Matias; Chih-Ming Chen; Daryl T-Y Lau; Stanley M Lemon; Hongmei Mo; Warren M Kati; Akhteruzzaman Molla
Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera.
Antiviral research 2007;73(1):40-9.
2006: F Blaine Hollinger; Daryl T-Y Lau
Hepatitis B: the pathway to recovery through treatment.
Gastroenterology clinics of North America 2006;35(4):895-931.
2006: Ned Snyder; Leka Gajula; Shu-Yuan Xiao; James Grady; Bruce A Luxon; Daryl T-Y Lau; Roger Soloway; John Petersen
APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C.
Journal of clinical gastroenterology 2006;40(6):535-42.
2006: F Blaine Hollinger; Daryl T-Y Lau
Hepatitis B: the pathway to recovery through treatment.
Gastroenterology clinics of North America 2006;35(2):425-61, x.
2006: Anne C SPAULDING; Cindy M Weinbaum; Daryl T-Y Lau; Richard Sterling; Leonard B Seeff; Harold S Margolis; Jay H Hoofnagle
A framework for management of hepatitis C in prisons.
Annals of internal medicine 2006;144(10):762-9.
2006: Yueh-Ming Loo; David M Owen; Kui Li; Andrea Erickson; Cynthia L Johnson; Penny M Fish; D Spencer Carney; Ting Wang; Hisashi Ishida; Mitsutoshi Yoneyama; Takashi Fujita; Takeshi Saito; William M Lee; Curt H Hagedorn; Daryl T-Y Lau; Steven Weinman; Stanley M Lemon; Michael Gale
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(15):6001-6.
2005: Daryl T-Y Lau; Alex T Hewlett
Screening for hepatitis A and B antibodies in patients with chronic liver disease.
The American journal of medicine 2005;118 Suppl 10A():28S-33S.
2005: karla helbig; Daryl T-Y Lau; Ljiljana Semendric; Hugh A J Harley; Michael R Beard
Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector.
Hepatology (Baltimore, Md.) 2005;42(3):702-10.
2005: Daryl T-Y Lau; Bruce A Luxon; Shu-Yuan Xiao; Michael R Beard; Stanley M Lemon
Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis.
Hepatology (Baltimore, Md.) 2005;42(2):273-81.
2005: Fernando E Membreno; Arturo L Baez; Reka Pandula; Eric M Walser; Daryl T-Y Lau
Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed.
Journal of gastroenterology and hepatology 2005;20(3):474-81.
2004: Daryl T-Y Lau; Fernando E Membreno
Antiviral therapy for treatment-naïve hepatitis B virus patients.
Gastroenterology clinics of North America 2004;33(3):581-99, ix-x.
2003: Daryl T-Y Lau; H Ma; Stanley M Lemon; Edward Doo; Marc G Ghany; Emil P Miskovsky; G L Woods; Y Park; Jay H Hoofnagle
A rapid immunochromatographic assay for hepatitis B virus screening.
Journal of viral hepatitis 2003;10(4):331-4.
2003: Alejandro Soza; Daryl T-Y Lau; Muhammad Farooq Khokhar; Hari S Conjeevaram; Yoon Park; Jay H Hoofnagle
Resolution of chronic hepatitis B-associated autoimmune neutropenia with interferon-alpha therapy.
Journal of pediatric gastroenterology and nutrition 2003;36(1):141-3.
2000: Daryl T-Y Lau; M F Khokhar; Edward Doo; Marc G Ghany; David Herion; Yoon Park; David E Kleiner; P Schmid; Lynn Condreay; Josée Gauthier; M C Kuhns; TSANYANG LIANG; Jay H Hoofnagle
Long-term therapy of chronic hepatitis B with lamivudine.
Hepatology (Baltimore, Md.) 2000;32(4 Pt 1):828-34.
1999: Daryl T-Y Lau; David E Kleiner; Yoon Park; A M Di Bisceglie; Jay H Hoofnagle
Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy.
Gastroenterology 1999;117(5):1229-33.
1999: Daryl T-Y Lau; K D Miller; Jill Detmer; Janice A Kolberg; Betsey Herpin; Julia A Metcalf; Richard Davey; Jay H Hoofnagle
Hepatitis G virus and human immunodeficiency virus coinfection: response to interferon-alpha therapy.
The Journal of infectious diseases 1999;180(4):1334-7.
1999: Daryl T-Y Lau; Edward Doo; Yoon Park; David E Kleiner; P Schmid; M C Kuhns; Jay H Hoofnagle
Lamivudine for chronic delta hepatitis.
Hepatology (Baltimore, Md.) 1999;30(2):546-9.
1998: Daryl T-Y Lau; David E Kleiner; Marc G Ghany; Yoon Park; P Schmid; Jay H Hoofnagle
10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.
Hepatology (Baltimore, Md.) 1998;28(4):1121-7.
1998: Daryl T-Y Lau; Lorraine Comanor; James Minor; James E Everhart; L J Wuestehube; Jay H Hoofnagle
Statistical models for predicting a beneficial response to interferon-alpha in patients with chronic hepatitis B.
Journal of viral hepatitis 1998;5(2):105-14.
1997: Daryl T-Y Lau; James E Everhart; David E Kleiner; Yoon Park; John Vergalla; P Schmid; Jay H Hoofnagle
Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.
Gastroenterology 1997;113(5):1660-7.